secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-10-24T23:59:59+00:00
Accession:  0001493152-25-019353
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics forms Scientific Advisory Board to advance RedTail platform and CLD-401
--------------------------------------------------------------------------------

- SAB members include Drs. Mace Rothenberg (ex-Pfizer CMO), Dmitriy Zamarin (Mount Sinai), John Wrangle (MUSC), David Curiel (WashU).
- RedTail platform uses enveloped vaccinia virus overexpressing CD55 for systemic delivery of genetic medicines to tumor sites.
- Lead candidate CLD-401, in IND-enabling studies, targets NSCLC, head & neck, and other cancers with high unmet need.
- CLD-401 is designed to home to metastases, replicate only in tumor cells, and express IL-15 superagonist.
- SAB will guide efficient development of CLD-401 into the clinic and advance RedTail platform utility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225019353/0001493152-25-019353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225019353/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer